minocycline and Erythema

Topics: Arthralgia; Erythema; Female; Fever; Humans; Lower Extremity; Middle Aged; Minocycline; Polyarteritis Nodosa

Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Diagnosis, Differential; Diet, Ketogenic; Drug Therapy, Combination; Erythema; Erythromycin; Exanthema; Female; Humans; Hyperpigmentation; Minocycline; Prurigo; Skin Cream; Treatment Outcome; Young Adult

Intense pulsed light (IPL) is a good option for erythema and telangiectasia of rosacea. Demodex, which is light and heat sensitive, is an important risk of Rosacea. Sometimes, IPL can induce rosacea aggravation. Here, we show two cases of erythema rosacea aggravated as pustule in several hours after IPL. Both cases show high density of Demodex after IPL. Neither of them had photosensitivity, systemic disease, or any other contraindication for IPL. One of the patients received IPL again after Demodex infection relieved and this time there was no inflammation induction. We need to attract more attention to IPL-induced rosacea aggravation and latent Demodex infection may act as a cofactor.

Topics: Adult; Animals; Anti-Bacterial Agents; Biopsy; Erythema; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Intense Pulsed Light Therapy; Middle Aged; Minocycline; Mite Infestations; Retrospective Studies; Rosacea; Skin; Skin Cream; Tacrolimus; Telangiectasis; Treatment Outcome

FMX101 4% contains 4% micronized minocycline (as an HCl) formulated in a lipophilic foam vehicle for topical administration. FMX101 4% has been shown to be an effective and well-tolerated treatment for moderate-to-severe acne in three Phase 3 pivotal studies, however, skin sensitization and toxicity potential remains to be fully evaluated. Four single-center, randomized, controlled, within-subject comparison studies were conducted to evaluate the potential for phototoxicity, photoallergy, skin sensitization, and cumulative skin irritation with topical administration of FMX101 4% and the corresponding vehicle. Across the four studies, healthy male and non-pregnant female volunteers (age ≥18 years) were randomized to FMX101 4%, vehicle, or other controls. In the phototoxicity study, treated skin was irradiated at 3 and 24 hr post-application, and local tolerability was assessed pre- and post-irradiation. In the photoallergy study, the skin was treated and irradiated (post-24 hr) twice weekly for 3 wk (induction phase), rested for 10-17 d, and naive skin sites were treated and irradiated (challenge phase); skin reactions were assessed after patch removal and post-irradiation. In the sensitization study, the skin was treated for 3 wk (induction phase), then rested for 10-14 d, and naive skin sites were treated for 48 hr (challenge phase); contact sensitization was assessed for both phases. In the cumulative irritation study, treatment and vehicle were applied daily for 21 d; skin irritation was assessed after each application. In all studies, standard safety assessments were conducted. A total of 32, 56, 233, and 42 subjects were enrolled in the phototoxicity, photoallergy, sensitization, and skin irritation studies, respectively. There was no evidence of phototoxicity, photoallergy, skin sensitization, or skin irritation potential with FMX101 4%. Few adverse events, mostly mild to moderate, were reported. In conclusion, FMX101 4% appeared to be well tolerated and non-irritating, and was considered to be non-sensitizing, non-phototoxic, and non-photoallergic.

Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Aged; Anti-Bacterial Agents; Clinical Trials, Phase I as Topic; Dermatitis, Photoallergic; Dermatitis, Phototoxic; Erythema; Female; Humans; Male; Middle Aged; Minocycline; Randomized Controlled Trials as Topic; Severity of Illness Index; Skin; Time Factors; Young Adult

Topics: Aged; Biomarkers; Biopsy; Drug Administration Schedule; Erythema; Facial Dermatoses; Humans; Immunohistochemistry; Lymphedema; Male; Mast Cells; Minocycline; Time Factors; Treatment Outcome

Topics: Adolescent; Adult; Anti-Bacterial Agents; Erythema; Female; Humans; Minocycline; Pyoderma Gangrenosum; Sjogren's Syndrome; Skin Diseases, Genetic

Patients with rosacea frequently report increased skin sensitivity, with features suggestive of an abnormal stratum corneum (SC) permeability barrier. Sebum, pH and hydration levels influence epidermal homeostasis. The correlation of changes in these parameters with clinically effective treatment has not been previously analysed.. To analyse sebum, pH and epidermal hydration levels of patients with papulopustular rosacea (PPR) before and after treatment with systemic minocycline.. We analysed sebum casual levels, pH and hydration along with erythema levels (as a marker of disease activity and response to treatment) on seven designated facial sites of 35 patients with active PPR and compared the results with values on the same sites of 34 control subjects with normal facial skin. To determine the effect of minocycline on these parameters, we re-examined the patients with PPR at the same sites after a 6-week course of treatment.. Patients with untreated PPR had significantly increased erythema indices, normal sebum casual levels, a more alkaline centrofacial region and reduced epidermal hydration levels compared with controls. Treatment with minocycline resulted in reduced erythema and increased hydration levels, with the most marked changes evident in the cheeks (13·3% reduction in erythema indices, P < 0·001; 12·4% increase in hydration levels, P = 0·012). There was no change in skin pH or sebum casual levels following treatment.. Patients with PPR have increased erythema indices, normal sebum casual levels, a more alkaline centrofacial region and reduced epidermal hydration levels compared with control subjects. Treatment with systemic minocycline reduces erythema and increases hydration, in the absence of any change in skin pH or sebum casual levels.

Topics: Adult; Aged; Body Water; Case-Control Studies; Dermatologic Agents; Electric Capacitance; Erythema; Facial Dermatoses; Female; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Minocycline; Rosacea; Sebum; Treatment Outcome

Topics: Aged; Anti-Infective Agents, Local; Ceftriaxone; Erythema; Female; Fever; Humans; Minocycline; Ofloxacin; Povidone-Iodine; Rickettsia Infections; Severity of Illness Index; Treatment Outcome

Topics: Administration, Oral; Adolescent; Anti-Bacterial Agents; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythema; Follow-Up Studies; Humans; Immunohistochemistry; Male; Minocycline; Severity of Illness Index; Skin Diseases, Papulosquamous; Thoracic Wall; Treatment Outcome

Topics: Administration, Topical; Anti-Bacterial Agents; Anti-Infective Agents; Diagnosis, Differential; Edema; Erythema; Facial Dermatoses; Humans; Male; Metronidazole; Middle Aged; Minocycline; Syndrome; Time Factors; Treatment Outcome

A patient with erythema elevatum diutinum (EED) developed pyoderma gangrenosum (PG). Investigation revealed an IgA kappa monoclonal gammopathy. Previous reports of PG in association with EED are reviewed and the spectrum of the neutrophilic dermatoses discussed.

Topics: Adult; Dapsone; Drug Therapy, Combination; Erythema; Humans; Immunoglobulin A; Male; Minocycline; Monoclonal Gammopathy of Undetermined Significance; Prednisolone; Pyoderma Gangrenosum

A 64-year-old male was admitted to our division because of fever. After admission, the patient was given beta-lactam antibiotics intravenously because he had no eruption and eschar. However, the fever continued, and he became unconsciousness and DIC appeared. We diagnosed the patient as Tsutsugamushi disease from indirect fluorescent antibody technique. Minocycline was excellently effective. Several reports of Tsutsugamushi disease without eruption have been given, so we must always be careful of Tsutsugamushi disease.

Topics: Antibodies, Bacterial; Erythema; Humans; Male; Middle Aged; Minocycline; Orientia tsutsugamushi; Scrub Typhus

Topics: Anti-Bacterial Agents; Clinical Trials as Topic; Erythema; Humans; Josamycin; Minocycline; Rosacea

Between December 1978 and July 1985, we used various antibiotics for the treatment of 97 adult patients with early erythema migrans disease (EMD). Six patients with borrelial lymphocytoma (BL) and 20 with acrodermatitis chronica atrophicans (ACA) were treated similarly. Follow-up was for a median of 20, 14, and 12 months, respectively. The erythema migrans and all associated symptoms resolved within a median of 3 weeks (0.5-18.4), BL within 7 weeks (4-16), and ACA partly or completely within several months. A Jarisch-Herxheimer (-like) reaction was observed in 8 patients with EMD. Fourteen patients with EMD and one with ACA developed an exacerbation of symptoms or new manifestations between the 2nd and 20th day, and 28 patients with EMD and one with ACA continued to have or acquired various symptoms greater than or equal to 3 weeks after initiation of therapy. Arthralgia, neurologic and constitutional symptoms, and in one instance a slight pulmonary interstitial edema developed in EMD. More severe initial illness was a risk factor for the development of later symptoms in EMD. Retreatment was more often necessary in ACA than in EMD. A patient with ACA had a recurrence after 5 1/2 years. IgG antibody titers rose at least fourfold in 5 patients with ACA and in 1 with EMD despite therapy. We tentatively recommend minocycline or high doses of parenteral penicillin for the treatment of these disorders.

Topics: Acrodermatitis; Adult; Anti-Bacterial Agents; Borrelia Infections; Erythema; Erythromycin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Minocycline; Penicillins; Tetracycline